Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02935686 · ClinicalTrials.gov registry record · Phase 1
A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults
A Phase 1 study, sponsored by Janssen Vaccines & Prevention B.V..
- Completed
- Registry status
- Phase 1
- Development phase
- 155
- Enrollment target
NCT02935686 is a Phase 1 study that has completed, run by Janssen Vaccines & Prevention B.V.. The registered enrollment target is 155 participants.
The verdict
NCT02935686, a Phase 1 study, has completed, sponsored by Janssen Vaccines & Prevention B.V..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 155 participants
- Enrollment target
Study Summary
The primary purpose of this study is to assess safety/tolerability of the different vaccine regimens and of a late boost vaccination; and to assess envelope (Env)-binding antibody (Ab) responses of the 2 different vaccine regimens.
Interventions
- OTHER Placebo
- BIOLOGICAL Ad26.Mos4.HIV
- BIOLOGICAL Clade C gp140 plus adjuvant
- BIOLOGICAL Clade C gp140/Mosaic gp140 plus adjuvant
- BIOLOGICAL gp140 HIV Bivalent Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2017-03-31 |
| Est. Completion | 2023-11-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02935686
The ClinicalTrials.gov registry entry for NCT02935686 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 155 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Vaccines & Prevention B.V., which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT02935686 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02935686 about?
NCT02935686 is a clinical study titled "A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults". The primary purpose of this study is to assess safety/tolerability of the different vaccine regimens and of a late boost vaccination; and to assess envelope (Env)-binding antibody (Ab) responses of the 2 different vaccine regimens.
What is the current status of trial NCT02935686?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 155 participants. The study started on 2017-03-31. Estimated completion is 2023-11-22.
What interventions are being tested in trial NCT02935686?
The interventions under investigation include: Placebo (OTHER), Ad26.Mos4.HIV (BIOLOGICAL), Clade C gp140 plus adjuvant (BIOLOGICAL), Clade C gp140/Mosaic gp140 plus adjuvant (BIOLOGICAL), gp140 HIV Bivalent Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02935686?
This trial is sponsored by Janssen Vaccines & Prevention B.V., which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.